Alabama Medical Cannabis 9% Excise Tax — Revenue Allocation & AMCC Funding

Last verified: May 2026

The 9% Excise Tax

Alabama Code § 20-2A-71 imposes a 9% excise tax on the gross retail sales of medical cannabis. The tax is collected by licensed dispensaries at point of sale and remitted monthly to the Alabama Department of Revenue. Patients see the excise tax line-itemized on their receipts.

The 9% rate is the second-lowest medical-cannabis excise tax in any U.S. state program — only New Mexico (no medical-cannabis excise) and Maryland (none on medical) impose lower medical-cannabis taxes. Most state programs have medical excise taxes ranging from 0% (Maryland, New Mexico, some other patient-friendly programs) to 8–15% (Florida, Michigan, others) to 20%+ (some New England states).

Layered Tax Burden

Compassion Act medical cannabis is also subject to:

• Alabama state sales tax (4%).
• County sales tax (variable, typically 1–3%). Montgomery County, Jefferson County (Birmingham), Mobile County, and Madison County (Huntsville) have county sales taxes. The county portion is collected and remitted alongside state sales tax.
• Municipal sales tax (variable, typically 0–5%). City sales taxes apply for sales within municipal limits. Birmingham has a 4% municipal sales tax; Montgomery has 3.5%; Mobile has 5%; Huntsville has 4.5%.

Total out-the-door tax on medical cannabis in Alabama typically ranges 14–18% depending on jurisdiction. A $100 pre-tax sale at Callie’s Apothecary in Montgomery (with state 4% + county 2.5% + municipal 3.5%) is taxed at 9% excise + 4% state + 2.5% county + 3.5% municipal = 19% total, producing a $119 out-the-door price.

Revenue Allocation

Excise-tax revenue is allocated under Compassion Act § 20-2A-71 as follows:

• Alabama Medical Cannabis Commission (AMCC) operating budget — primary funding source for AMCC staffing, program oversight, license review, and patient-registry administration.
• Alabama Medical Cannabis Patient Registry — the database tracking patient registrations, certifying-physician registrations, and dispensing transactions.
• Alabama Department of Public Health (ADPH) compliance work — ADPH’s role in Compassion Act enforcement.
• Alabama Department of Agriculture and Industries (ADAI) industrial-hemp oversight — the parallel hemp regulatory program.

The Compassion Act does not earmark excise revenue for general-fund programs (education, transportation, social-services). All revenue is allocated to program-administrative or related-regulatory functions. This is unusual among state programs — many state medical-cannabis excise revenues fund schools, mental-health services, or general funds.

The Revenue Forecast

Alabama’s small initial dispensary footprint (one operational dispensary as of May 2026; potentially 4 within 12 months) and the form-restricted product slate produce limited revenue. The AMCC’s pre-launch revenue projections estimated $30–50 million in annual sales at full operational capacity (37 dispensary storefronts), which would produce $2.7–4.5 million in annual 9% excise revenue.

For comparison: Mississippi’s MMCP — with a comparable population (~3 million vs. Alabama’s ~5 million) but a more permissive product slate and a larger initial dispensary footprint — reached $300 million in cumulative sales by mid-2025 since its January 2023 launch. Alabama’s excise revenue in 2026 will be a fraction of that.

The Revenue-vs-Access Trade-Off

The 9% rate reflects a deliberate policy choice. Patient advocates argued during the 2021 legislative process that high excise rates reduce program access, particularly for low-income patients who cannot afford the layered tax burden. The 9% excise + ~5% sales tax produces a moderate burden — lower than tobacco-product excise (which often exceeds 30% in some states) but higher than ordinary pharmaceutical sales tax (which is often zero on prescription drugs).

The Compassion Act’s form-restriction (no flower, no edibles, no vape carts) raises base-product costs because pharmaceutical-form manufacturing requires GMP compliance and pharmaceutical packaging. The combination of high base costs + 14–18% out-the-door tax burden produces program-access constraints for low-income patients. Sliding-scale and patient-assistance programs from individual dispensaries have begun to emerge, but no statewide patient-assistance framework exists.

Insurance Non-Coverage

Health insurance does not cover Compassion Act medical cannabis. Federal Schedule I status (despite the April 2026 Schedule III order) prevents Medicare, Medicaid, Tricare, VA coverage, and private commercial insurance coverage of cannabis as a medication. Patients pay 100% out-of-pocket for both the dispensary cost and the layered tax burden.

Some federal Health Savings Account (HSA) and Flexible Spending Account (FSA) administrators have refused to permit medical-cannabis purchases as qualified medical expenses, even with a certifying-physician recommendation. The federal-tax characterization of cannabis as a Schedule I substance creates compliance friction for HSA/FSA reimbursement.

The Federal Tax Layer — IRC § 280E

Internal Revenue Code § 280E denies federal tax deductions for ordinary business expenses to businesses "trafficking in controlled substances" listed in Schedule I or II. The provision applies to Compassion Act licensees because cannabis remains Schedule I federally despite the April 2026 Schedule III order (the order’s effective date and full implementation timeline remain pending). The § 280E burden raises licensee operating costs, which licensees pass to consumers as higher product prices.

If the April 2026 Schedule III implementation is finalized, § 280E would no longer apply to cannabis, dramatically reducing licensee tax burden. The reduction would create downward pressure on consumer prices — though licensees would likely retain part of the savings as margin recovery rather than passing all of it to consumers.

Practical Notes

• Plan for 14–18% out-the-door tax. The base price on the menu does not include tax.
• Bring cash or debit. Credit cards are not accepted due to federal banking restrictions.
• Track dispensary spending for HSA/FSA discussions. Some administrators may permit reimbursement; others will not.
• Insurance does not cover the cost. Plan for full out-of-pocket.